Unresectable Renal Cell Carcinoma Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0115886 (Unresectable Renal Cell Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03829111CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney CancerTreatment